Danaher Co. (NYSE:DHR) Shares Purchased by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC raised its stake in Danaher Co. (NYSE:DHR) by 778.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,808 shares of the conglomerate’s stock after acquiring an additional 8,692 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Danaher were worth $2,252,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the third quarter valued at approximately $50,000. Darwin Wealth Management LLC acquired a new stake in Danaher during the third quarter worth approximately $55,000. Finally, Modus Advisors LLC acquired a new stake in Danaher during the fourth quarter worth approximately $56,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Danaher stock opened at $239.83 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s fifty day moving average price is $235.52 and its 200 day moving average price is $253.65. The company has a market capitalization of $173.22 billion, a price-to-earnings ratio of 45.77, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. On average, research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Barclays reduced their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Finally, Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.